KEYSTONE SYMPOSIA
on Molecular and Cellular Biology

Antibodies and Vaccines as Drugs for COVID-19 (EK31)

January 13-14, 2021 • Virtual at your computer

Scientific Organizers: David P. Humphreys, Pierre Bruhns, Patrick C. Wilson and Esther Breij

Sponsored by 10x Genomics, BioLegend, Inc., Genentech, Inc., Genmab A/S and Merck & Co., Inc.

WEDNESDAY, JANUARY 13

Antibodies as Drugs for COVID-19 (7am Denver/Mountain Time Start)

*__David P. Humphreys__, UCB Pharma, UK

*__Esther Breij__, Genmab, Netherlands

__Bo Barnhart__, Abcellera Biologics Inc., Canada
Combating COVID-19: Identifying a Potential Drug Candidate for Human Testing in 90 Days

__Christos Kyratsous__, Regeneron Pharmaceuticals Inc, USA
Rapid Selection, Characterization and Clinical Development of Fully-Human Antibodies Against Emerging Infectious Diseases

__Davide Corti__, Vir Biotechnology, Switzerland
Cross-Neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody

__X. Sunney Xie__, Peking University, China
COVID-19 Neutralizing Antibodies Screened by Single Cell Genomics

__Linqi Zhang__, Tsinghua University, China
Human Neutralizing Antibodies Elicited by SARS-CoV-2 Infection

__Xavier Saelens__, Ghent University, Belgium
When Size Matters: A Broadly Neutralizing Single Domain Antibody to Prevent and Treat COVID-19

__Michael Stumpp__, Molecular Partners, Switzerland
Highly Potent Anti-SARS-CoV-2 Multivalent DARP in Therapeutic Candidates

__Michael G. Ison__, Northwestern/Celltrion, Inc., USA
Therapeutic Effect of Regdanvimab (CT-P59) in Patients with Mild to Moderate Symptoms of SARS-CoV-2 Infection

__Natalia Freund__, Tel Aviv University, Israel
Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors

Poster Session (11am Denver/Mountain Time Start)

THURSDAY, JANUARY 14

Vaccines as Drugs for COVID-19 (7am Denver/Mountain Time Start)

*__David P. Humphreys__, UCB Pharma, UK

*__Pierre Bruhns__, Institut Pasteur, France

__Liise-anne Pirofski__, Albert Einstein College of Medicine and Montefiore Medical Center, USA
The Challenges of a New Vaccine for a New Disease

__Paul F. McKay__, Imperial College, UK
Development of a Self-Amplifying RNA Vaccine for COVID-19

__Andrea Carfi__, Moderna, USA
Potent Vaccine Efficacy from mRNA-1273 Expressing SARS-CoV-2 Spike Protein Stabilized in the Prefusion Conformation

__Alexander Muik__, BioNTech, Germany
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

__Trevor RF Smith__, Inovio, USA
Development of INO-4800, a DNA Vaccine for COVID-19

__Sarah Catherine Gilbert__, University of Oxford, UK
Development of ChAdOx1 nCoV-19 (AZD1222); Creating a Vaccine in a Pandemic Setting

__Hanneke Schuitemaker__, Janssen Vaccines & Prevention B.V., Netherlands
Janssen's Efforts in the Development of an Ad26 Based COVID-19 Vaccine

__Susanne Rauch__, CureVac GmbH, Germany
Development of the mRNA based SARS-CoV-2 Vaccine CVnCoV

__Neeltje van Doremalen__, NIAID, National Institutes of Health, USA
Intranasal Vaccination with ChAdOx1 nCoV-19 Results in Reduced Nasal Shedding and Lack of Lower Respiratory Tract Infection in SARS-CoV-2 Hamsters and Rhesus macaques

Networking Lounge (10am Denver/Mountain Time Start)